IO Biotech, Inc. (IOBT )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol IOBT
- Company IO Biotech, Inc.
- Price $1.55
- Changes Percentage 9.12
- Change 0.1295
- Day Low $1.23
- Day High $1.65
- Year High $1.73
- Year Low $0.66
- Market Cap $79,715,901
- Price Avg 50 EMA (D) $1.01
- Price Avg 200 EMA (D) $1.02
- Exchange NASDAQ
- Volume 78,747
- Average Volume 157,301
- Open $1.47
- Previous Close $1.42
- EPS -1.49
- PE -0.81
- Earnings Announcement 2025-08-08 12:00:00
- Shares Outstanding $65,880,910
Company brief: IO BIOTECH, INC. (IOBT )
- Healthcare
- Biotechnology
- Dr. Mai-Britt Zocca Ph.D.
- https://www.iobiotech.com
- DK
- N/A
- 11-05-2021
- US4497781090
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
IOBT Corporation News
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?
zacks.com -- After reaching an important support level, IO Biotech, Inc. (IOBT) could be a good stock pick from a technical perspective. IOBT recently experienced a "golden cross" event, which saw its 50-day simpl...